首頁 > 市場調查報告書 > 醫療設備

心血管設備循環系統

市場調查報告書

商品編碼

1623006

2024 年至 2031 年心房顫動藥物市場（按產品類型、應用、最終用戶和地區劃分）

Atrial Fibrillation Drugs Market By Product, Type, Application, End User & Region for 2024-2031

出版日期: 2024年09月25日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

心房顫動藥物市場評估，2024 年至 2031 年

隨著人口不斷增長，尤其是老年人口，肥胖和高血壓等與生活方式相關的風險因素的發生率不斷上升，這加強了對早期發現和治療的需求，為心房顫動藥物市場創造了巨大的機會。根據 Verified Market Research 分析師的預測，心房顫動藥物市場在 2023 年的價值預計將達到 147.8 億美元，並在預測期內達到 199.1 億美元的估值。

持續的研究努力專注於新的治療技術，例如抗心律不整藥物、抗凝血劑和心率控制藥物的開發，將進一步增加心房顫動藥物市場的擴張，使市場從 2024 年到 2031 年的複合年增長率達到 3.8%。

心房顫動藥物市場：定義/概述

心房顫動藥物是專門用於管理和治療心房顫動的藥物，心房顫動是一種常見的心律不整，其特徵是源自心臟上腔（心房）的心律不整、心跳加速。這些藥物在治療心房顫動方面發揮多種作用，包括恢復正常心律（竇性心律）、控制心率、降低血栓和中風的風險。

此外，通常會開立抗心律不整藥物來恢復規律的心跳，而控制心率藥物則旨在將心率保持在正常範圍內。此外，由於心房顫動患者心律不整導致血栓風險更高，因此醫生通常會給他們開抗凝血劑，以防止血栓形成，降低中風的風險。

慢性病的高發性將如何影響心房顫動藥物市場？

全球心房顫動盛行率的不斷上升是市場發展的主要驅動力。心房顫動是最常見的嚴重心律不整，影響全世界數百萬人，迫切需要新的治療方法。隨著人口老化以及高血壓、糖尿病、肥胖等潛在疾病的盛行率增加，心房顫動的盛行率也隨之增加。

全球醫療保健支出的增加，尤其是已開發經濟體和新興經濟體的醫療保健支出的增加，促進了心房顫動藥物市場的擴張。由於醫療保健優先考慮高品質的治療和治療結果，人們更加關注有效管理心房顫動等慢性病，而使用創新療法可以改善患者的治療結果並降低長期醫療成本。

此外，早期發現和治療心房顫動對於預防中風和心臟衰竭等後果變得越來越重要。隨著穿戴式科技和可監測心律和識別異常的行動健康應用程式的普及，早期檢測也推動了市場擴張。這些努力將增加被診斷為心房顫動的人數，並擴大需要藥物治療的患者數量。

心房顫動藥物的副作用對市場意味著什麼？

許多用於治療心房顫動的藥物，特別是抗凝血劑，都有嚴重的副作用，包括出血問題。這些安全問題限制了某些藥物在某些患者中的使用，並使醫療保健專業人員和患者對藥物治療心房顫動猶豫不決，從而限制了市場的成長。

當心房顫動市場關鍵藥物的專利到期時，仿製藥的競爭就會出現，從而大大減少原廠藥製造商的收入。仿製藥雖然降低了藥品價格，但也對市場構成了課題，因為它降低了投資創新和新藥研究的動力。

此外，儘管心房顫動在全球流行，但由於成本高、醫療基礎設施缺乏以及醫療服務提供者和患者缺乏認識，許多新興國家仍然無法獲得現代治療選擇，包括現代抗凝血劑。社會經濟因素和醫療保健系統的差異進一步加劇了這項課題，阻礙了這些地區心房顫動藥物市場的擴張。

Rising rates of lifestyle-related risk factors such as obesity and hypertension among the growing population, especially geriatric populace, is bolstering the demand for early detection and treatment, creating immense opportunities for Atrial Fibrillation Drugs Market. According to the analyst from Verified Market Research, the Atrial Fibrillation Drugs Market is estimated to reach a valuation of USD 19.91 Billion over the forecast subjugating aroundUSD 14.78 Billion valued in 2023.

Ongoing research efforts focusing on novel therapeutic techniques, such as the development of anti-arrhythmic medicines, anticoagulants, and rate control pharmaceuticals, are further increasing Atrial Fibrillation Drugs Market expansion and enabling the market to grow at aCAGR of 3.8% from 2024 to 2031.

Atrial Fibrillation Drugs Market: Definition/ Overview

Atrial fibrillation drugs are medications that are specifically intended to manage and treat atrial fibrillation, a common heart rhythm disease characterized by irregular and fast heartbeats that originate in the heart's upper chambers (atria). These medications perform a variety of functions in the treatment of atrial fibrillation, including restoring normal heart rhythm (sinus rhythm), managing heart rate, and lowering the risk of blood clots and stroke.

Furthermore, anti-arrhythmic drugs are commonly prescribed to assist restore a regular heart rhythm, whereas rate control medications try to keep the heart rate within normal limits. Also, anticoagulant drugs are often prescribed to prevent blood clot development and lower the risk of stroke, as people with atrial fibrillation have a higher risk of blood clots due to their irregular heartbeat.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will High Prevalence of Chronic Illnesses Affect the Atrial Fibrillation Drugs Market?

The growing prevalence of atrial fibrillation around the world is a significant driver of the market. Atrial fibrillation is the most frequent type of severe arrhythmia, affecting millions of people globally, increasing the need for new treatment alternatives. Ageing populations, as AFib incidence rises with age, as well as rising rates of underlying diseases such as hypertension, diabetes, and obesity, all contribute to rising prevalence.

Increased global healthcare spending, particularly in developed and emerging economies, contributes to the expansion of the Atrial Fibrillation Drugs Market. With healthcare systems prioritizing quality care and outcomes, there is a greater emphasis on the effective management of chronic illnesses such as atrial fibrillation This involves the use of innovative treatment alternatives, which can improve patient outcomes and lower long-term healthcare expenditures.

Furthermore, early identification and treatment of atrial fibrillation are becoming increasingly important in preventing consequences such as stroke and heart failure. Early detection through the widespread use of wearable technology and mobile health apps that can monitor cardiac rhythms and identify anomalies also helps to drive market expansion. These initiatives increase the number of people diagnosed with atrial fibrillation, which broadens the patient pool that requires drug therapy.

What will Side Effects of Atrial Fibrillation Drugs have on the Market?

Many drugs used to treat atrial fibrillation, particularly anticoagulants, are associated with substantial side effects, such as bleeding problems. These safety concerns limit the use of specific medications in particular patients cause healthcare practitioners and patients to be hesitant about managing atrial fibrillation pharmacologically, and limiting market growth.

The expiration of patents for important medications in the atrial fibrillation market allows for generic competition, substantially decreasing revenue for pharmaceutical companies that produced the original branded drugs. While generics make drugs more affordable, they also pose a challenge to the market by reducing incentives for innovation and investment in new medication research.

Furthermore, despite the global prevalence of atrial fibrillation, many emerging economies still have limited access to modern treatment options, including the most recent anticoagulants, due to high costs, a lack of healthcare infrastructure, and a lack of awareness among healthcare providers and patients. This difficulty is exacerbated by socioeconomic reasons and differences in healthcare systems, which impede the expansion of the atrial fibrillation medication market in these locations.

Category-Wise Acumens

What are the Drivers that Contribute to the Demand for the Anticoagulant segment?

According to VMR analysis, the anticoagulant drugs segment is estimated to hold the largest market share during the forecast period. The global growth in atrial fibrillation prevalence has led to an increase in the demand for better stroke prevention methods. Anticoagulant medications, particularly NOACs, are the cornerstone of stroke prevention in atrial fibrillation patients, which contributes to their market dominance. The emphasis on lowering the risk of stroke in atrial fibrillation patients with appropriate anticoagulant medication contributes to the segment's sustained expansion and dominance.

Novel Oral Anticoagulants (NOACs) have been proven to be as effective as or more effective than Vitamin K Antagonists (VKAs) such as warfarin, with a better safety profile, particularly in terms of lowering the risk of significant bleeding problems. NOACs also have less food-drug interactions than VKAs, making them a more convenient choice for patients. This increased efficacy and safety profile has resulted in a high preference for NOACs among healthcare providers and patients, contributing to the anticoagulant drug segment's dominance.

Furthermore, clinical recommendations from top cardiology and thrombosis associations throughout the world increasingly advocate NOACs over VKAs for the majority of AFib patients due to their favorable benefit-risk profile. These guidelines have an impact on prescribing practices and have played a crucial role in the broad adoption of NOAC. The robust endorsement by clinical guidelines assures that NOACs continue their leading position in the anticoagulant drug market.

What are the Potential Factors for the Dominance of Paroxysmal Type in the Market?

The paroxysmal segment is estimated to dominate the Atrial Fibrillation Drugs Market during the forecast period. Paroxysmal Atrial Fibrillation, which is characterized by the abrupt start of irregular heartbeats that stop within seven days (typically resolving within 24 hours), is common since it is frequently the first phase of atrial fibrillation in many people. Drugs aimed at this segment are in more demand because of their episodic character, which often makes it the first kind of atrial fibrillation to be recognized and treated.

Paroxysmal atrial fibrillation is generally treated with a combination of medicines, ranging from anticoagulants to prevent strokes to antiarrhythmic drugs to regulate rhythm. This variety of treatment alternatives can help the segment get a greater market share because it includes a wide range of pharmaceuticals that can be adapted to particular patient needs, as well as newer and more advanced pharmacological breakthroughs.

Furthermore, effectively managing paroxysmal atrial fibrillation can stop or slow the development of more chronic and persistent forms of the condition, which are more difficult to treat and have a higher risk of problems. This therapeutic potential supports a high emphasis on early and effective treatment techniques, including medication therapies, which contributes to the segment's dominance in the Atrial Fibrillation Drugs Market.

Country/Region-wise Acumens

What are the Factors that Contribute to North America's Competitive Edge in the Market?

According to VMR analyst, North America is estimated to dominate the Atrial Fibrillation Drugs Market during the forecast period. North America, particularly the United States, has a high frequency of cardiovascular disorders, including atrial fibrillation, which is caused by variables such as ageing populations, lifestyle choices, and obesity. This results in a large patient pool requiring atrial fibrillation treatment, which fuels demand for atrial fibrillation drugs.

The region has advanced healthcare systems that provide extensive access to cutting-edge medical technology and treatments. This infrastructure promotes early diagnosis, treatment innovation, and successful management of atrial fibrillation, resulting in higher acceptance rates of innovative atrial fibrillation medications than other locations.

Furthermore, North America is a pharmaceutical research and development hotspot, with a significant emphasis on innovative drug therapies. The presence of major pharmaceutical companies, as well as significant investment in R&D activities, help to accelerate the release of novel and effective atrial fibrillation medications, boosting market expansion in the region.

Will Flourishing Healthcare Infrastructure in Asia Pacific Boom Atrial Fibrillation Drugs Market?

Asia Pacific region is estimated to exhibit the highest growth in the market during the forecast period. Asia Pacific is experiencing a substantial demographic shift, with increasing ageing populations, particularly in Japan and China. Older age is a significant risk factor for atrial fibrillation, resulting in an increasing patient population in need of atrial fibrillation treatments and driving demand for atrial fibrillation medications in the region.

This region is experiencing significant advances in healthcare infrastructure and increased healthcare spending. Countries are investing in better healthcare infrastructure and treatment access, making modern atrial fibrillation medications more accessible to the general public, hence driving market expansion.

Furthermore, in the Asia-Pacific region, there is growing awareness of atrial fibrillation and associated complications. When combined with increased healthcare access and insurance coverage, this leads to higher diagnostic rates and treatment uptake, driving the expansion of the Atrial Fibrillation Drugs Market.

Competitive Landscape

The competitive landscape of the Atrial Fibrillation Drugs Market is marked by fierce competition among several players vying for a significant market share. In addition, market participants frequently pursue strategic partnerships, collaborations, and acquisitions to boost their market position and broaden their product ranges.

Some of the prominent players operating in the Atrial Fibrillation Drugs Market include:

Abbott Laboratories, Bristol-Myers Squibb, Johnson & Johnson, Pfizer Inc., Novartis AG, Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Daiichi Sankyo Company, Limited, Boehringer Ingelheim GmbH, AstraZeneca PLC, Bayer AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Medtronic plc, Shionogi & Co., Ltd., Astellas Pharma Inc., Meda Pharmaceuticals, and Cardionomic Therapeutics Inc.

Latest Developments

In October 2023, Bristol-Myers Squibb announced favorable findings from the Phase 3 PEACH-AF trial. The experiment assessed the efficacy and safety of the investigational medication, lixisenatide, in preventing stroke in individuals with AF.

In September 2023, Pfizer Inc. announced a collaboration with Apple to create a new wearable device that can detect and monitor AF via a person's smartphone.

In April 2023, Johnson & Johnson presented results at the American College of Cardiology meeting that demonstrated the long-term safety and efficacy of their medicine, Edoxaban, in avoiding stroke in patients with AF.

1 INTRODUCTION OF GLOBAL ATRIAL FIBRILLATION DRUGS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model

5 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY PRODUCT

5.1 Overview
5.2 Antiarrhythmic Drug
5.3 Anticoagulant Drugs
- 5.3.1 Vitamin K Antagonists
- 5.3.2 Novel Oral Anticoagulants

6 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY TYPE

6.1 Overview
6.2 Paroxysmal
6.3 Persistent
6.4 Permanent

7 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY APPLICATION

7.1 Overview
7.2 Heart Rhythm Control
7.3 Heart Rate Control

8 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY END USER

8.1 Overview
8.2 Hospitals
8.3 Cardiac Centers
8.4 Ambulatory Surgical Centers

9 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe & Africa
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East & Africa

10 GLOBAL ATRIAL FIBRILLATION DRUGS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Abbott Laboratories
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Bristol-Myers Squibb
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Johnson & Johnson
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Pfizer Inc.
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Novartis AG
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 F. Hoffmann-La Roche Ltd
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Sanofi S.A.
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Merck & Co., Inc.
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11. 9 Daiichi Sankyo Company, Limited
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Boehringer Ingelheim GmbH
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments